{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ruiz-Ciancio D"],"funding":["NHLBI NIH HHS","NCI NIH HHS"],"pagination":["698-712"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10469072"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33"],"pubmed_abstract":["Despite improvements in B cell acute lymphoblastic leukemia (B-ALL) treatment, a significant number of patients experience relapse of the disease, resulting in poor prognosis and high mortality. One of the drawbacks of current B-ALL treatments is the high toxicity associated with the non-specificity of chemotherapeutic drugs. Targeted therapy is an appealing strategy to treat B-ALL to mitigate these toxic off-target effects. One such target is the B cell surface protein CD22. The restricted expression of CD22 on the B-cell lineage and its ligand-induced internalizing properties make it an attractive target in cases of B cell malignancies. To target B-ALL and the CD22 protein, we performed cell internalization SELEX (Systematic Evolution of Ligands by EXponential enrichment) followed by molecular docking to identify internalizing aptamers specific for B-ALL cells that bind the CD22 cell-surface receptor. We identified two RNA aptamers, B-ALL1 and B-ALL2, that target human malignant B cells, with B-ALL1 the first documented RNA aptamer interacting with the CD22 antigen. These B-ALL-specific aptamers represent an important first step toward developing novel targeted therapies for B cell malignancy treatments."],"journal":["Molecular therapy. Nucleic acids"],"pubmed_title":["Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia."],"pmcid":["PMC10469072"],"funding_grant_id":["R01 CA138503","R01 HL139581","P30 CA086862"],"pubmed_authors":["Di Bartolo AL","Lin LH","Sanchez D","Mestre MB","Ruiz-Ciancio D","Barros MN","Masone D","Giangrande PH","Veeramani S","Thiel WH"],"additional_accession":[]},"is_claimable":false,"name":"Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemia.","description":"Despite improvements in B cell acute lymphoblastic leukemia (B-ALL) treatment, a significant number of patients experience relapse of the disease, resulting in poor prognosis and high mortality. One of the drawbacks of current B-ALL treatments is the high toxicity associated with the non-specificity of chemotherapeutic drugs. Targeted therapy is an appealing strategy to treat B-ALL to mitigate these toxic off-target effects. One such target is the B cell surface protein CD22. The restricted expression of CD22 on the B-cell lineage and its ligand-induced internalizing properties make it an attractive target in cases of B cell malignancies. To target B-ALL and the CD22 protein, we performed cell internalization SELEX (Systematic Evolution of Ligands by EXponential enrichment) followed by molecular docking to identify internalizing aptamers specific for B-ALL cells that bind the CD22 cell-surface receptor. We identified two RNA aptamers, B-ALL1 and B-ALL2, that target human malignant B cells, with B-ALL1 the first documented RNA aptamer interacting with the CD22 antigen. These B-ALL-specific aptamers represent an important first step toward developing novel targeted therapies for B cell malignancy treatments.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-06-23T03:17:42.06Z","creation":"2025-04-20T03:47:16.728Z"},"accession":"S-EPMC10469072","cross_references":{"pubmed":["37662970"],"doi":["10.1016/j.omtn.2023.07.028"]}}